Showing results (1-10 of 420) with videos related to

Sort By:
Pageof 42
European Journal of Cancer (Oxford, England : 1990)|August 15, 2022
Comparative efficacy of novel combination strategies for unresectable hepatocellular carcinoma: A network metanalysis of phase III trialsClaudia A M Fulgenzi, Antonio D'Alessio, Chiara Airoldi, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 17, 2020
Combined PD-1/VEGFR Blockade: A New Era of Treatment for Hepatocellular CancerDavid J Pinato, Petros Fessas, Alessio Cortellini, et al.
Chemotherapy|January 9, 2022
New Frontiers in the Medical Therapy of Hepatocellular CarcinomaClaudia Angela Maria Fulgenzi, Antonio D'Alessio, Thomas Talbot, et al.
Expert Review of Molecular Diagnostics|March 3, 2022
Predictive biomarkers of response to immune checkpoint inhibitors in hepatocellular carcinomaAmbreen Muhammed, Antonio D'Alessio, Andrei Enica, et al.
Journal of Hepatocellular Carcinoma|August 13, 2021
PD-1 Blockade for Hepatocellular Carcinoma: Current Research and Future ProspectsAntonio D'Alessio, Lorenza Rimassa, Alessio Cortellini, et al.
International Journal of Cancer|November 6, 2024
Prior antibiotics, proton pump inhibitors, and probiotics in patients with extensive stage small cell lung cancer treated with immune checkpoint blockade: A post-hoc analysis of the phase I/III IMpower 133 trialKazuki Takada, Shinkichi Takamori, Mototsugu Shimokawa, et al.
Future Oncology (London, England)|April 25, 2023
PETAL protocol: a phase Ib study of pembrolizumab after transarterial chemoembolization in hepatocellular carcinomaPetros Fessas, Bernhard Scheiner, Antonio D'Alessio, et al.
Thoracic Cancer|May 15, 2026
Impact of Anti-Inflammatory Drug Therapy on the Efficacy of First-Line Atezolizumab Treatment in Patients With Advanced Non-Small Cell Lung Cancer: An Integrated Analysis of Five Randomized Controlled TrialsKazuki Takada, Alessio Cortellini, Shinkichi Takamori, et al.
Lung Cancer (Amsterdam, Netherlands)|October 17, 2025
Probiotic supplement exposure and outcomes of patients with non-small cell lung cancer treated with first-line atezolizumab therapy: Pooled analysis of individual patient data from five randomized control trialsKazuki Takada, Mototsugu Shimokawa, Alessio Cortellini, et al.
JHEP Reports : Innovation in Hepatology|September 10, 2021
ALBI grade: Evidence for an improved model for liver functional estimation in patients with hepatocellular carcinomaCoskun O Demirtas, Antonio D'Alessio, Lorenza Rimassa, et al.
Pageof 42